US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Marker Therapeutics, Inc. - Common Stock (NQ:MRKR)

1.050 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Marker Therapeutics, Inc. - Common Stock

Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 12/11
Via Investor Brand Network
News headline image
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights... 
Via Newsfile
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 7/24
Via Investor Brand Network
Marker Therapeutics Inc. (NASDAQ: MRKR) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Marker Therapeutics (NASDAQ: MRKR) Announces Leadership Transition and Strategic Partnership with CellReady to Strengthen Financial Position Through 2025
Houston-based Marker Therapeutics, Inc. (Nasdaq: MRKR) operates as a clinical-stage company focused on developing advanced T cell-based immunotherapies for hematological 
Via Spotlight Growth
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death